Eric Hsu
Corporate Officer/Principal bei INMED PHARMACEUTICALS INC.
Vermögen: 15 $ am 31.05.2024
Aktive Positionen von Eric Hsu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| INMED PHARMACEUTICALS INC. | Corporate Officer/Principal | 13.03.2018 | - |
Karriereverlauf von Eric Hsu
Ehemalige bekannte Positionen von Eric Hsu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Geschäftsführer | 01.01.2002 | 01.01.2018 |
| Technik-/Wissenschafts-/F&E-Leiter | 01.01.2002 | 01.01.2018 |
Ausbildung von Eric Hsu
| McGill University | Undergraduate Degree |
| University of Toronto | Doctorate Degree |
Statistik
International
| Kanada | 5 |
Operativ
| Chief Operating Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INMED PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
